A kind of janagliflozin metformin tablets and preparation method thereof
Through the metformin hydrochloride sustained release layer and gagliflozin instant release layer compound preparation of metformin hydrochloride, the problems of poor blood sugar control and missed medication in type II diabetes were solved, and more efficient and safe sugar reduction was achieved Effectiveness and better therapeutic dependency.
Patent Information
- Application Number
- CN202411107704.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-13
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-08-13
AI Technical Summary
The existing single oral antidiabetic drugs are difficult to take into account the problems of insufficient insulin secretion and increased glucagon secretion in type II diabetes, resulting in unsatisfactory blood sugar control effect and missed medications affecting the treatment effect.
A compound preparation of metformin hydrochloride sustained release layer and gazliflozin instant release layer was developed to synergistically lower the glycemic reduction through different mechanisms, reduce the missed drug and improve the dependence of treatment.
It achieves more efficient blood sugar control, reduces missed medication, improves the dependence and safety of treatment, is convenient to apply, and meets the requirements of generic drugs consistency.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medical technology, and in particular to a janagliflozin metformin tablet and a preparation method thereof. Background Art
[0002] At present, there are about 100 million people suffering from type II diabetes in the world, which is characterized by hyperglycemia caused by excessive liver glucose production and peripheral insulin resistance. Hyperglycemia is considered to be the main risk factor for the formation of diabetic complications and may be directly related to the impaired insulin secretion of late type II diabetes. Therefore, it can be expected that normalization of insulin can improve the blood sugar of type II diabetic patients.
[0003] Type 2 diabetes (T2DM) causes insufficient insulin secretion and increased glucagon secretion. A single oral hypoglycemic drug cannot take care of both symptoms at the same time, making it difficult for patients to achieve ideal blood sugar control. Aiming at the pathogenesis of type 2 diabetes, combining drugs with different hypoglycemic mechanisms can make up for the treatment limitations of a single oral hypoglycemic drug and achieve more lasting and effective blood sugar control.
[0004] Janagliflozin is a sodium glucose co-transporter 2 (SGLT-2) inhibitor independently developed by the applicant. Janagliflozin tablets can be used to treat type II diabetes. It has excellent efficacy, high safety, and no side effects of traditional oral hypoglycemic drugs such as hypoglycemia and weight gain. Currently, as a national Class I innovative drug, it has been approved for marketing by the National Drug Administration. Metformin hydrochloride is a classic hypoglycemic drug that can reduce fasting and postprandial hyperglycemia in patients with type II diabetes. The results of clinical trials that have been conducted on Janagliflozin tablets combined with metformin for the treatment of type II diabetes patients have shown that it can significantly improve blood sugar, reduce weight, and lower systolic blood pressure in patients with type II diabetes, and can improve high-density lipoprotein cholesterol (HDLC) metabolism, increase insulin sensitivity, and have good long-term clinical efficacy.
[0005] However, there are still some problems with combined medication, among which missed medication is an important reason for blood sugar reaching the target. Fixed-dose combination preparations (FDC) can not only synergize blood sugar reduction through different mechanisms and achieve a more efficient blood sugar reduction effect, but also reduce missed medication and improve treatment dependence. Therefore, the development of compound preparations that are easy to use and safe has important clinical significance and broad market prospects. Summary of the invention
[0006] In order to solve the above technical problems, the present invention provides a janagliflozin metformin tablet and a preparation method thereof. The janagliflozin metformin tablet provided by the present invention is easy to use, has good safety and stability, can not only synergistically reduce blood sugar through different mechanisms, achieve a more efficient blood sugar reduction effect, but also can reduce drug missed doses and improve treatment dependence.
[0007] In a first aspect, the present invention provides a janagliflozin metformin tablet, comprising a metformin hydrochloride sustained-release layer, a janagliflozin immediate-release layer and a coating layer;
[0008] The metformin hydrochloride sustained-release layer comprises:
[0009] Metformin hydrochloride→1000 parts by weight;
[0010] Adhesive a→40-60 parts by weight;
[0011] Lubricant a→3-17 parts by weight;
[0012] Sustained release matrix material → 235-393 parts by weight;
[0013] Glidant a→3-17 parts by weight;
[0014] The janagliflozin immediate-release layer comprises:
[0015] Janagliflozin → 37.488 parts by weight;
[0016] Filler → 240-260 parts by weight;
[0017] Disintegrant → 2.4-9.6 parts by weight;
[0018] Adhesive b→2.4-13.4 parts by weight;
[0019] Glidant b→0-2.4 parts by weight;
[0020] Lubricant b→0-2.4 parts by weight.
[0021] Wherein, the janagliflozin used in the janagliflozin immediate-release layer of the present invention is a co-crystal of janagliflozin and proline (1:2), and the co-crystal molecular formula is C 25 H 29 ClO6·2C5H9NO2 (the crystal structure is recorded in patent CN109476624B); therefore, C 25 H 29 ClO6·2C5H9NO2, the dosage is 37.488 parts by weight. 25 H 29 Based on ClO6, the dosage is 25 parts by weight.
[0022] In the metformin hydrochloride sustained-release layer, the binder a may be 40 parts by weight, 45 parts by weight, 50 parts by weight, 55 parts by weight, 60 parts by weight, etc.
[0023] The lubricant a may be 3 parts by weight, 5 parts by weight, 8 parts by weight, 10 parts by weight, 15 parts by weight, 17 parts by weight, etc.
[0024] The sustained-release skeleton material may be 235 parts by weight, 250 parts by weight, 300 parts by weight, 350 parts by weight, 393 parts by weight, etc.
[0025] The amount of the glidant a can be 3 parts by weight, 5 parts by weight, 10 parts by weight, 15 parts by weight, 17 parts by weight, etc.
[0026] In the janagliflozin immediate-release layer, the filler may be 240 parts by weight, 245 parts by weight, 250 parts by weight, 255 parts by weight, 260 parts by weight, etc.
[0027] The disintegrant may be 2.4 parts by weight, 5 parts by weight, 6 parts by weight, 9.6 parts by weight, etc.
[0028] The binder b can be 2.4 parts by weight, 5 parts by weight, 8 parts by weight, 10 parts by weight, 13.4 parts by weight, etc.
[0029] The glidant b can be 0 parts by weight, 1.5 parts by weight, 2 parts by weight, 2.4 parts by weight, etc.
[0030] The lubricant b can be 0 parts by weight, 1.5 parts by weight, 2 parts by weight, 2.4 parts by weight, etc.
[0031] As a preferred technical solution of the present invention, the metformin hydrochloride sustained-release layer comprises:
[0032] Metformin hydrochloride→1000 parts by weight;
[0033] Adhesive a→50.01 parts by weight;
[0034] Lubricant a→7 parts by weight;
[0035] Sustained release matrix material → 235 parts by weight;
[0036] Glidant a→13 parts by weight;
[0037] The janagliflozin immediate-release layer comprises:
[0038] Janagliflozin → 37.488 parts by weight;
[0039] Filler → 251.7 parts by weight;
[0040] Disintegrant → 6 parts by weight;
[0041] Adhesive b→2.4 parts by weight;
[0042] Glidant b→1.2 parts by weight;
[0043] Lubricant b→1.2 parts by weight.
[0044] The present invention finds that in the metformin hydrochloride sustained-release layer, when the amount of glidant a is too much and the amount of lubricant a is too little, the tablet gel layer after dissolution is more thoroughly moistened, and the tablet core is basically free of opaque lumps, which is slightly different from the phenomenon after dissolution of the metformin hydrochloride sustained-release tablet control preparation; and when the amount of glidant a is too little and the amount of lubricant a is too much, the compressibility deteriorates and the tablet hardness decreases. Therefore, the present invention preferably has a ratio of glidant a to lubricant a in the metformin hydrochloride sustained-release layer of 13 parts by weight: 7 parts by weight.
[0045] As a preferred technical solution of the present invention, the binder a and the binder b are independently selected from any one or more of sodium carboxymethyl cellulose, povidone, polyvinyl pyrrolidone, copovidone or starch slurry.
[0046] As a preferred technical solution of the present invention, the lubricant a and the lubricant b are independently selected from any one or more of magnesium stearate, calcium stearate, zinc stearate, stearic acid, sodium stearyl fumarate, polyethylene glycol or sodium lauryl sulfate.
[0047] As a preferred technical solution of the present invention, the sustained-release matrix material is selected from hypromellose and / or hydroxypropyl cellulose.
[0048] As a preferred technical solution of the present invention, the glidant a and the glidant b are independently selected from any one or more of silicon dioxide, magnesium silicate, magnesium trisilicate or talc.
[0049] As a preferred technical solution of the present invention, the filler is selected from any one or more of lactose, microcrystalline cellulose, mannitol, corn starch, pregelatinized starch, sorbitol, dextrin, sucrose or calcium hydrogen phosphate.
[0050] As a preferred technical solution of the present invention, the disintegrant is selected from any one or more of cross-linked carboxymethyl cellulose sodium, cross-linked carboxymethyl cellulose calcium, cross-linked povidone, low-substituted hydroxypropyl cellulose, dry starch or sodium carboxymethyl starch.
[0051] As a preferred technical solution of the present invention, the filler is selected from a combination of lactose and microcrystalline cellulose.
[0052] As a preferred technical solution of the present invention, the filler comprises:
[0053] Lactose → 36-216 parts by weight;
[0054] Microcrystalline cellulose → 35.7-215.7 parts by weight.
[0055] Wherein, the lactose may be 36 parts by weight, 126 parts by weight, 216 parts by weight, etc.
[0056] The microcrystalline cellulose may be 35.7 parts by weight, 125.7 parts by weight, 215.7 parts by weight, etc.
[0057] As a preferred technical solution of the present invention, the metformin hydrochloride sustained-release layer comprises:
[0058] Metformin hydrochloride→1000 parts by weight;
[0059] Sodium carboxymethyl cellulose → 50.01 parts by weight;
[0060] Magnesium stearate → 7 parts by weight;
[0061] Hydroxypropyl methylcellulose → 235 parts by weight;
[0062] Silicon dioxide → 13 parts by weight;
[0063] The janagliflozin immediate-release layer comprises:
[0064] Janagliflozin → 37.488 parts by weight;
[0065] Lactose → 126 parts by weight;
[0066] Microcrystalline cellulose → 125.7 parts by weight;
[0067] Cross-linked sodium carboxymethyl cellulose → 6 parts by weight;
[0068] Povidone → 2.4 parts by weight;
[0069] Silicon dioxide → 1.2 parts by weight;
[0070] Magnesium stearate→1.2 parts by weight.
[0071] The present invention finds that in the janagliflozin immediate-release layer, when the amount of microcrystalline cellulose is too much and the amount of lactose is too little, the prepared particles are not formed and are in a relatively dry fine powder; while when the amount of microcrystalline cellulose is too little and the amount of lactose is too much, the prepared particles have good formability, but there are more large particles after granulation, which is not conducive to uniform mixing. Therefore, the present invention preferably microcrystalline cellulose: lactose = 125.7 parts by weight: 126 parts by weight.
[0072] As a specific embodiment of the present invention, the composition of the janagliflozin metformin tablets is shown in Table 1:
[0073] Table 1
[0074]
[0075] The present invention finds that when the total weight of the janagliflozin immediate-release layer is about 300 mg, the weight of the janagliflozin immediate-release layer tablet is more stable during the tablet compression process.
[0076] As a preferred technical solution of the present invention, the hypromellose is hypromellose K100M; the microcrystalline cellulose is microcrystalline cellulose 101; the lactose is lactose GranuLac200; and the povidone is povidone K30.
[0077] As a preferred technical solution of the present invention, the particle size D90 of the metformin hydrochloride is ≤200 μm, for example, 10 μm, 50 μm, 100 μm, 150 μm, 200 μm, etc.
[0078] In a second aspect, the present invention provides a method for preparing the janagliflozin metformin tablets according to the first aspect, the preparation method comprising:
[0079] (1) Mixing a formula amount of metformin hydrochloride, a binder a and an internal lubricant a, wet granulating, drying and granulating, and mixing the dried granules with a formula amount of a sustained-release matrix material, a glidant a and an external lubricant a to obtain a metformin hydrochloride sustained-release layer mixture;
[0080] (2) mixing the formulated amount of janagliflozin, filler, internal disintegrant and binder b, wet granulating, drying and granulating, and mixing the dried granules with the formulated amount of external disintegrant, glidant b and lubricant b to obtain a janagliflozin immediate-release layer mixture;
[0081] (3) The metformin hydrochloride sustained-release layer mixture and the janagliflozin immediate-release layer mixture are compressed into double-layer tablets and coated to obtain the janagliflozin metformin tablets.
[0082] As a preferred technical solution of the present invention, the preparation method comprises:
[0083] (1) Mixing a formula amount of metformin hydrochloride, sodium carboxymethyl cellulose and internally added magnesium stearate, wet granulating, drying and granulating, and mixing the dried granules with a formula amount of hypromellose, silicon dioxide and externally added magnesium stearate to obtain a metformin hydrochloride sustained-release layer mixture;
[0084] (2) mixing the formulated amount of janagliflozin, lactose, microcrystalline cellulose, internal croscarmellose sodium and povidone, wet granulating, drying and granulating, and mixing the dried granules with the formulated amount of external croscarmellose sodium, silicon dioxide and magnesium stearate to obtain a janagliflozin immediate-release layer mixture;
[0085] (3) The metformin hydrochloride sustained-release layer mixture and the janagliflozin immediate-release layer mixture are compressed into double-layer tablets and coated to obtain the janagliflozin metformin tablets.
[0086] As a preferred technical solution of the present invention, the step (1) is: putting the formulated amount of metformin hydrochloride, sodium carboxymethyl cellulose and internal magnesium stearate into a wet granulator, premixing under stirring and shearing, adding purified water, wet granulating, wet granulating, drying, dry granulating to obtain dry granules, mixing the dry granules with the formulated amount of hypromellose and silicon dioxide, and continuing to add external magnesium stearate to mix, to obtain a metformin hydrochloride sustained-release layer mixture.
[0087] As a preferred technical solution of the present invention, the step (1) is: putting the formula amount of metformin hydrochloride, sodium carboxymethyl cellulose and internal magnesium stearate into a wet granulator, premixing for 3-8 min at a stirring rate of 10-25 Hz and a shear rate of 1000-2000 rmp, adding purified water for a control time of ≤5 min, wet granulating for 2-5 min at a stirring rate of 10-25 Hz and a shear rate of 1000-2000 rmp, using an 8-mesh sieve for wet granulation, controlling the inlet air temperature to 50-60°C and the fan frequency to 15-25 Hz for drying until the moisture content of the material is ≤1.5% at 40-45°C, drying is completed, performing dry granulation with a 0.8 mm / 1.0 mm sieve, and the finishing speed is 500-1000 rpm to obtain dry granules, mixing the dry granules with the formula amount of hydroxypropyl methylcellulose and silicon dioxide for 5-15 min, and continuing to add external magnesium stearate and mixing for 2-8 min, to obtain the metformin hydrochloride sustained-release layer mixture.
[0088] As a preferred technical solution of the present invention, the step (1) is: putting the formula amount of metformin hydrochloride, sodium carboxymethyl cellulose and internal magnesium stearate into a wet granulator, premixing for 5 min at a stirring rate of 15 Hz and a shear rate of 1500 rmp, adding purified water for a control time of ≤5 min, wet granulating for 2-5 min at a stirring rate of 10-25 Hz and a shear rate of 1500 rmp, using an 8-mesh sieve for wet granulation, controlling the inlet air temperature to 50-60°C and the fan frequency to 15-25 Hz for drying until the moisture content of the material is ≤1.5% at 40-45°C, drying is completed, and 0.8 mm / 1.0 mm sieve dry granulation is performed at a finishing speed of 500-1000 rpm to obtain dry granules, mixing the dry granules with the formula amount of hydroxypropyl methylcellulose and silicon dioxide for 10 min, and continuing to add external magnesium stearate and mix for 5 min to obtain a metformin hydrochloride sustained-release layer mixture.
[0089] As a preferred technical solution of the present invention, the step (2) further comprises: mixing the formulated amount of povidone with an ethanol solution to prepare a 3% povidone-ethanol adhesive solution.
[0090] As a preferred technical solution of the present invention, the step (2) is: putting the formulated amount of jangliflozin, lactose, microcrystalline cellulose, and internally added cross-linked sodium carboxymethyl cellulose into a wet granulator, premixing under stirring and shearing, adding a povidone solution, wet granulating, wet granulating, drying, dry granulating to obtain dry granules, mixing the dry granules with the formulated amount of externally added cross-linked sodium carboxymethyl cellulose and silicon dioxide, and continuing to add magnesium stearate to mix, to obtain a jangliflozin immediate-release layer mixture.
[0091] As a preferred technical solution of the present invention, the step (2) is: putting the formula amount of gagliflozin, lactose, microcrystalline cellulose and cross-linked sodium carboxymethyl cellulose into a wet granulator, premixing for 3-8 minutes at a stirring rate of 10-25 Hz and a shear rate of 1000-2000 rmp, adding the povidone solution at a stirring rate of 20-35 Hz and a shear rate of 1000-2000 rmp for a control time of ≤4 minutes, wet granulating for 2-4 minutes at a stirring rate of 20-35 Hz and a shear rate of 1000-2000 rmp, using an 8-mesh sieve for wet granulation, controlling the inlet air temperature to 50-60°C for drying until the moisture content of the material is ≤2.8% at 40-45°C, drying is completed, and 0.8 mm / 1.0 mm sieve dry granulation is performed at a finishing speed of 500-1000 rpm to obtain dry granules, and mix the dry granules with the formulated amount of additional cross-linked sodium carboxymethyl cellulose and silicon dioxide for 5-15 min, and continue to add magnesium stearate and mix for 2-8 min to obtain a jangliflozin immediate-release layer mixture.
[0092] As a preferred technical solution of the present invention, the step (2) is: putting the formula amount of gagliflozin, lactose, microcrystalline cellulose, and internal cross-linked sodium carboxymethyl cellulose into a wet granulator, premixing for 5 min at a stirring rate of 15 Hz and a shear rate of 1500 rmp, adding the povidone solution at a stirring rate of 20-35 Hz and a shear rate of 1500 rmp for a control time of ≤4 min, wet granulating for 2-4 min at a stirring rate of 20-35 Hz and a shear rate of 1500 rmp, using an 8-mesh sieve for wet granulation, controlling the inlet air temperature to 50-60°C for drying until the moisture content of the material is ≤2.8% at 40-45°C, drying is completed, performing dry granulation with a 0.8 mm / 1.0 mm sieve, and the finishing speed is 500-1000 rpm to obtain dry granules, mixing the dry granules with the formula amount of external cross-linked sodium carboxymethyl cellulose and silicon dioxide for 10 min, and continuing to add magnesium stearate and mix for 5 min to obtain the janagliflozin immediate-release layer mixture.
[0093] As a preferred technical solution of the present invention, during tableting in step (3), the hardness of the tablet is controlled to be 260-350 N, for example, 260 N, 280 N, 300 N, 320 N, 350 N, etc.
[0094] The present invention adopts a 20.3×10.8 mm special-shaped punch during tableting, installs a suitable track, and calculates the tablet weight: the tablet weight of gagliflozin = 25 mg / intermediate product content (mg / g), the tablet weight of metformin hydrochloride sustained-release tablet = 1000 mg / intermediate product content (mg / g), the tablet weight difference of the compound tablet is controlled within ±5%, and the filling depth and tablet thickness are adjusted so that the tablet hardness of the compound tablet is 260-350N.
[0095] As a preferred technical solution of the present invention, in step (3), the coating weight gain is controlled to be 4-5%, for example, 4%, 4.2%, 4.4%, 4.6%, 4.8%, 5%, etc.
[0096] As a preferred technical solution of the present invention, the method for preparing the coating solution comprises: mixing the film coating premix with ethanol, and diluting with purified water to obtain the coating solution.
[0097] As a preferred technical solution of the present invention, the solid content of the coating solution is 20%.
[0098] As a preferred technical solution of the present invention, the coating liquid needs to be sieved through a 100-mesh sieve before coating.
[0099] During coating, the present invention controls the air inlet temperature to 35-45°C, the main engine speed to 6 rpm, pours the coated tablets into the coating pot, and when the material temperature reaches above 35°C, adjusts the main engine speed to 6-12 rpm, the peristaltic pump speed to 2-6mL / min, the atomization pressure to 0.2MPa, and maintains negative pressure in the pot during the coating process. Take 10 tablets every half an hour during the coating process and weigh them. When the weight gain reaches 4%, weigh them every 10-15 minutes to calculate the coating weight gain until the coating weight gain meets the requirements.
[0100] The technical solution provided by the embodiment of the present invention has the following advantages compared with the prior art:
[0101] The janagliflozin metformin tablets provided by the present invention are easy to use, safe and reliable, have good dissolution behavior, meet the requirements of generic drug consistency, and have excellent stability. They can not only synergistically lower blood sugar through different mechanisms to achieve a more efficient blood sugar lowering effect, but also reduce drug missed doses and improve treatment dependence. DETAILED DESCRIPTION
[0102] In order to more clearly understand the above-mentioned objectives, features and advantages of the present invention, the scheme of the present invention will be further described below. It should be noted that the embodiments of the present invention and the features in the embodiments can be combined with each other without conflict.
[0103] In the following description, many specific details are set forth to facilitate a full understanding of the present invention, but the present invention may also be implemented in other ways different from those described herein; it is obvious that the embodiments in the specification are only part of the embodiments of the present invention, rather than all of the embodiments.
[0104] In the embodiments of the present invention, the imported original preparation of metformin hydrochloride sustained-release tablets Glucophage XR (serial number 12-52), specification 0.5g, licensed by Merck Serono Limited, published in the "Catalogue of Generic Drug Reference Preparations" (12th batch) published by the State Drug Administration (NMPA) is used as the control preparation of metformin hydrochloride sustained-release laminated tablets in janagliflozin metformin sustained-release tablets. Janagliflozin tablets (specification 25 mg) developed by Jilin Huisheng Biopharmaceutical Co., Ltd. are used as the control preparation of janagliflozin immediate-release laminated tablets in janagliflozin metformin sustained-release tablets.
[0105] Example 1
[0106] This example explores the effect of the dosage of HPMC on the dissolution behavior of the metformin hydrochloride sustained-release layer in the jangliflozin metformin tablets. HPMC is a sustained-release skeleton material, and its dosage directly affects the release of the sustained-release layer. This example uses the dissolution curve of metformin hydrochloride as an indicator to explore the effect of the dosage of HPMC on the dissolution behavior of metformin hydrochloride.
[0107] (1) The preparation method of metformin hydrochloride comprises: crushing the metformin hydrochloride raw material by a pulverizer, and D90 is ≤200 μm. According to Table 2, the metformin hydrochloride and sodium carboxymethyl cellulose in the formula amount are put into a wet granulator, premixed for 5 min at a stirring rate of 15 Hz and a shear rate of 1500 rmp, adding purified water while maintaining the stirring and shearing state, and controlling the water addition time to be ≤5 min, wet granulating for 2-5 min at a stirring rate of 10-25 Hz and a shear rate of 1500 rmp, and wet granulating with an 8-mesh stainless steel sieve. Set the inlet air temperature to 50-60°C and the fan frequency to 15-25 Hz for drying until the moisture content of the material is ≤1.5% at 40-45°C (105°C, automatic end point), if the moisture content is >1.5%, continue drying, and sample the material moisture content every 5 min. After drying, the dried granules were sieved through a 0.8 mm / 1.0 mm sieve at a finishing speed of 500-1000 rpm. The amount of additional excipients was calculated according to the dry granule yield, and the granules were mixed with the formulated amount of hydroxypropyl methylcellulose and silicon dioxide for 10 min. Magnesium stearate was then added and mixed for 5 min to obtain a metformin hydrochloride sustained-release layer mixture, which was tableted to obtain a metformin hydrochloride sustained-release layer.
[0108] The formula of the metformin hydrochloride is shown in Table 2:
[0109] Table 2
[0110]
[0111] (2) Dissolution behavior test: Using phosphate buffer with pH = 6.8 as the dissolution medium, the paddle method was 100 revolutions, and the dissolution rate and release rate were determined according to the first method of 0931 of the fourth volume of the 2020 edition of the Chinese Pharmacopoeia: Dissolution and release rate determination method. After 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, and 12 h, samples were taken for testing and the dissolution rate of metformin hydrochloride (%) was calculated. The results are shown in Table 3:
[0112] Table 3
[0113]
[0114] As shown in Table 3, as the dosage of HPMC decreases, the dissolution behavior of metformin hydrochloride sustained-release tablets is slightly faster, and when the dosage of HPMC is 235-393 mg / tablet, the dissolution behavior is similar; preferably, 235 mg is considered as the dosage of HPMC in the formulation.
[0115] Example 2
[0116] This example investigates the effect of the amount of sodium carboxymethylcellulose, an adhesive a, on the dissolution behavior of the metformin hydrochloride sustained-release layer in jangliflozin metformin tablets. The imported original preparation of metformin hydrochloride sustained-release tablets, Glucophage XR (serial number 12-52), with a specification of 0.5 g and a licensed manufacturer, Merck Serono Limited, in the "Catalogue of Generic Drug Reference Preparations" (12th batch) published by the National Medical Products Administration (NMPA) was used as the control preparation.
[0117] (1) The preparation method of metformin hydrochloride is the same as that in Example 1. The formula of metformin hydrochloride is shown in Table 4:
[0118] Table 4
[0119]
[0120] (2) The dissolution behavior test method is the same as that in Example 1. The results are shown in Table 5:
[0121] Table 5
[0122]
[0123] It can be found from Table 5 that when the dosage of the binder is 40 mg, 50.01 mg and 60 mg, respectively, there is no significant effect on the dissolution characteristics of metformin hydrochloride. The preferred dosage of the binder in the metformin hydrochloride sustained-release layer is 50.01 mg.
[0124] Example 3
[0125] This example investigates the effects of the amounts of lubricant a (magnesium stearate) and glidant a (silicon dioxide) on the dissolution behavior and compressibility of the metformin hydrochloride sustained-release layer in the janagliflozin metformin tablets.
[0126] (1) The preparation method of metformin hydrochloride is the same as that in Example 1. The formula of metformin hydrochloride is shown in Table 6:
[0127] Table 6
[0128]
[0129] (2) The dissolution behavior test method is the same as that in Example 1. The results are shown in Table 7:
[0130] Table 7
[0131]
[0132] (3) The compressibility results are shown in Table 8:
[0133] Table 8
[0134]
[0135] From Tables 7 and 8, it can be found that the amount of glidant a and lubricant a in the formula has no significant effect on the dissolution behavior of the tablets. However, the properties of the sustained-release tablets after dissolution are observed. The tablet gel layer of the formula SiO2 (silicon dioxide): MS (magnesium stearate) = 17:3 is more thoroughly wetted after dissolution, and the tablet core has basically no opaque lumps, which is slightly different from the phenomenon after dissolution of the control preparation. In addition, the amount of SiO2:Ms = 3:17 in the formula is too large, the compressibility is significantly deteriorated, and the tablet hardness decreases, so the amount ratio of glidant a to lubricant a in the formula is SiO2:Ms = 13:7.
[0136] In order to further adjust the effect of the lubricant on the entire metformin hydrochloride sustained-release layer, the inventors added magnesium stearate in the form of 5 mg of magnesium stearate internally and 2 mg of magnesium stearate externally.
[0137] Example 4
[0138] This example explores the effect of the dosage of the janagliflozin immediate-release layer on the janagliflozin metformin tablets.
[0139] The present invention uses the janagliflozin tablets (specification 25 mg) developed by Jilin Huisheng Biopharmaceutical Co., Ltd. as the control preparation of the janagliflozin immediate-release layer in the janagliflozin metformin sustained-release tablets. The core weight of the 25 mg janagliflozin tablet control preparation is 120 mg, and the size of the janagliflozin metformin sustained-release tablets is 20.3×10.8 mm. In this embodiment, it is found that when 120 mg of particles are spread on a 20.3×10.8 mm die, the particles are not enough to cover the die, so it is necessary to increase the weight of the janagliflozin layer so that the particles can be spread on the die surface better and maintain good tablet weight stability during tableting.
[0140] In this example, the weight of the janagliflozin immediate-release layer was 300 mg (Example 4-1) and 260 mg (Example 4-2), and the tableting results are shown in Table 9:
[0141] Table 9
[0142]
[0143] It can be seen from Table 9 that when the tablet weight of janagliflozin was about 300 mg, the RSD of the tablet content during the tableting process was 2.1%. The tablet weight of janagliflozin was relatively stable during the tableting process. Therefore, the amount of janagliflozin immediate-release layer in janagliflozin metformin tablets was increased to about 300 mg for the preparation of compound tablets.
[0144] Even if the tablet weight of the janagliflozin immediate-release layer is increased to about 300 mg, it is still impossible to use a 20.3×10.8 mm die to compress the single tablet for research. In addition, the amount of hydropropyl methylcellulose in the metformin hydrochloride sustained-release layer will affect the release of the janagliflozin immediate-release layer. Therefore, when conducting prescription process screening, the janagliflozin immediate-release layer needs to be compressed into a janagliflozin-metformin compound tablet before conducting a dissolution study of the janagliflozin immediate-release layer.
[0145] Example 5
[0146] This example investigates the effect of the amount of fillers (microcrystalline cellulose and lactose) on the dissolution behavior and powder data of the janagliflozin immediate-release layer in the janagliflozin metformin tablets.
[0147] 1. The preparation method of janagliflozin metformin tablets comprises:
[0148] (1) Crush the metformin hydrochloride API with a pulverizer to a D90 of ≤200 μm; put the metformin hydrochloride, sodium carboxymethyl cellulose and internal magnesium stearate a1 in the formula amount according to Table 10 into a wet granulator, premix for 5 min at a stirring rate of 15 Hz and a shear rate of 1500 rmp, and add purified water while maintaining the stirring and shearing state, and control the water addition time to be ≤5 min;
[0149] Wet granulation was performed for 2-5 min at a stirring rate of 10-25 Hz and a shear rate of 1500 rmp, and wet granulation was performed using an 8-mesh stainless steel sieve; the inlet air temperature was set to 50-60°C and the fan frequency was set to 15-25 Hz for drying until the moisture content of the material was ≤1.5% at 40-45°C (105°C, automatic endpoint); if the moisture content was >1.5%, drying was continued, and samples were taken every 5 min to determine the moisture content of the material; after drying, the dried granules were sieved with a 0.8 mm / 1.0 mm sieve, and the finishing speed was 500-1000 rpm to obtain dry granules;
[0150] The amount of the additional excipients is calculated according to the dry granule yield, and mixed with the formulated amount of hydroxypropyl methylcellulose and silicon dioxide a for 10 min, and then the additional magnesium stearate a2 is added and mixed for 5 min to obtain a metformin hydrochloride sustained-release layer mixture, and a sample is taken for intermediate product testing;
[0151] (2) Mixing the formulated amount of povidone K30 with the ethanol solution, stirring and dissolving to prepare a 3% povidone K30-ethanol adhesive solution;
[0152] The formulated amount of jangliflozin, lactose GranuLac200, microcrystalline cellulose 101, and croscarmellose sodium b1 were sequentially put into the wet granulator, and premixed for 5 min at a stirring rate of 15 Hz and a shear rate of 1500 rmp; 3% povidone K30-ethanol binder solution was added at a stirring rate of 20-35 Hz and a shear rate of 1500 rmp, and the liquid addition time was controlled to be ≤4 min;
[0153] Set the stirring rate to 20-35 Hz and the shear rate to 1500 rmp for wet granulation for 2-4 minutes, use an 8-mesh stainless steel screen for wet granulation, control the inlet air temperature to 50-60°C, and dry until the moisture content of the material is ≤2.8% (105°C, 5 minutes) at 40-45°C. If the moisture content is >2.8%, continue drying, and sample the material every 5 minutes to measure the moisture content. After drying, perform dry granulation with a 0.8 mm / 1.0 mm screen, and the finishing speed is 500-1000 rpm to obtain dry granules.
[0154] The amount of the additional excipients was calculated according to the dry granule yield, and mixed with the additional cross-linked sodium carboxymethyl cellulose b2 and silicon dioxide b in the formula for 10 min, and magnesium stearate b was added and mixed for 5 min to obtain the jangliflozin immediate-release layer mixture, and samples were taken for intermediate product testing;
[0155] (3) The metformin hydrochloride sustained-release layer and the gagliflozin immediate-release layer were mixed and compressed into double-layer tablets using a 20.3 × 10.8 mm special-shaped punch and a suitable track. The tablet weight was calculated and the weight difference of the composite tablets was controlled within ±5%. The filling depth and tablet thickness were adjusted to ensure that the hardness of the composite tablets was 260-350N.
[0156] The formula of the janagliptin metformin tablets is shown in Table 10:
[0157] Table 10
[0158]
[0159] 2. Dissolution test: pH = 6.8 phosphate buffer + 0.02% SDS was used as the dissolution medium, the paddle method was 75 revolutions, and the dissolution rate and release rate were determined according to the first method of 0931 of the fourth general rules of the Chinese Pharmacopoeia 2020 edition: dissolution and release rate determination method. After 5 min, 10 min, 15 min, 30 min, 45 min, and 60 min, samples were taken for testing and the dissolution (%) of metformin hydrochloride was calculated. The results are shown in Table 11:
[0160] Table 11
[0161]
[0162] 3. Powder data see Table 12:
[0163] Table 12
[0164]
[0165] It can be found from Table 11 that if the amount of microcrystalline cellulose in the prescription is too much, the first point of dissolution will be slowed down, but by adjusting the amount of microcrystalline cellulose and lactose, the cumulative dissolution of all tablets in 15 minutes is greater than 85%, which is a rapid dissolution, similar to the reference preparation. From the granulation phenomenon in Table 12, it can be found that when the microcrystalline cellulose: lactose in the prescription is 215.7:36, under the condition of the existing binder dosage, the prepared granules are not formed and are in a relatively dry fine powder. When the prescription microcrystalline cellulose: lactose is 35.7:216, the prepared granules have good formability, but there are more large particles after granulation, which is not conducive to uniform mixing. Therefore, the preferred prescription is microcrystalline cellulose: lactose = 125.7:126.
[0166] Example 6
[0167] This example investigates the effect of the amount of binder b (povidone) on the dissolution behavior of the janagliflozin immediate-release layer in the janagliflozin metformin tablets.
[0168] (1) The preparation method of the Janagliflozin Metformin Tablets is the same as that in Example 5. The formula of the Janagliflozin Metformin Tablets is shown in Table 13:
[0169] Table 13
[0170]
[0171] (2) The dissolution behavior test method is the same as that in Example 5. The results are shown in Table 14:
[0172] Table 14
[0173]
[0174] As shown in Table 14, when the dosage of the adhesive povidone K30 was between 2.4-13.4 mg / tablet, the 15-min cumulative dissolution rate of the immediate-release layer of janagliflozin was >85%, which was similar to the dissolution of the reference preparation.
[0175] Example 7
[0176] This example investigates the effect of the amount of disintegrant (cross-linked carboxymethyl cellulose sodium) on the dissolution behavior of the janagliflozin immediate-release layer in the janagliflozin metformin tablets.
[0177] (1) The preparation method of the Janagliflozin Metformin Tablets is the same as that in Example 5. The formula of the Janagliflozin Metformin Tablets is shown in Table 15:
[0178] Table 15
[0179]
[0180] (2) The dissolution behavior test method is the same as that in Example 5. The results are shown in Table 16:
[0181] Table 16
[0182]
[0183] It can be found from Table 16 that as the amount of added disintegrant decreases, the dissolution in 5 min slows down slightly, but the cumulative dissolution rate of the tablets in 15 min is greater than 85% when the amount of added disintegrant is different, which is similar to the dissolution behavior of the control preparation. Therefore, the preferred amount of disintegrant is 3.6 mg / tablet.
[0184] Example 8
[0185] This example investigates the effects of the amounts of lubricant b (magnesium stearate b) and glidant b (silicon dioxide b) on the dissolution behavior of the janagliflozin immediate-release layer in the janagliflozin metformin tablets.
[0186] (1) The preparation method of the Janagliflozin Metformin Tablets is the same as that in Example 5. The formula of the Janagliflozin Metformin Tablets is shown in Table 17:
[0187] Table 17
[0188]
[0189] (2) The dissolution behavior test method is the same as that in Example 5. The results are shown in Table 18:
[0190] Table 18
[0191]
[0192] It can be found from Table 18 that when the dosage of silicon dioxide b and magnesium stearate b is 2.4 mg, the 5 min dissolution point slows down slightly, and the end point dissolution is less than 95%. Based on the screening of multiple batches of small-scale test prescriptions, the fluidity and compressibility of the intermediate particles are good when the dosage of magnesium stearate b is 1.2 mg / tablet and the dosage of silicon dioxide b is 1.2 mg / tablet. Therefore, the dosage of silicon dioxide b and magnesium stearate b in the preferred prescription is 1.2 mg.
[0193] Example 9
[0194] This embodiment provides a janagliflozin metformin tablet and a preparation method thereof.
[0195] The preparation method of the janagliflozin metformin tablets is the same as that of Example 5, and the difference from Example 5 is that the preparation method of this example further includes the following steps (4) and (5):
[0196] (4) Preparation of coating solution: Prepare according to the theoretical prescription volume of 6%, the solid content of the coating solution is 20%, and the diluent is purified water. Slowly add the weighed film coating premix into ethanol, stir while adding until it is evenly dispersed, then add purified water, continue stirring for 40 minutes to mix evenly, and pass through a 100-mesh sieve before coating. Check whether the sieve is intact before and after sieving;
[0197] (5) Coating: Set the air inlet temperature to 35-45°C and the main engine speed to 6 rpm. Pour the coated tablets into the coating pot and measure the material temperature. When the material temperature reaches above 35°C, adjust the main engine speed to 6-12 rpm, the peristaltic pump speed to 2-6 mL / min, and the atomization pressure to 0.2 MPa. The pot should maintain negative pressure during the coating process. Take 10 tablets and weigh them every half an hour during the coating process. When the weight gain reaches 4%, weigh them every 10-15 minutes and calculate the coating weight gain until the coating weight gain reaches 5%. (Conventional gastric-soluble film coating, Shanghai Colorcon Coating Technology Co., Ltd.)
[0198] The formula of the janagliptin metformin tablets is shown in Table 19:
[0199] Table 19
[0200]
[0201] Note: Purified water and ethanol are used as solvents and are removed during the preparation process.
[0202] Performance Testing
[0203] The stability of the janagliflozin metformin tablets prepared in Example 9 was investigated. The stability results of the janagliflozin immediate-release layer are shown in Table 20, and the stability results of the metformin hydrochloride sustained-release layer are shown in Table 21:
[0204] Table 20
[0205]
[0206] Table 21
[0207]
[0208] It can be found from Tables 20 and 21 that after the janagliflozin metformin tablets prepared by the present invention were placed under 60°C, light, RH92.5% and accelerated (40°C, RH75%) conditions for 30 days, there was no obvious increase in related substances and the content was equivalent to that of the control preparation, indicating that the product had good stability.
[0209] It should be noted that, in this article, relational terms such as "first" and "second" are only used to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply any such actual relationship or order between these entities or operations. Moreover, the terms "include", "comprise" or any other variants thereof are intended to cover non-exclusive inclusion, so that a process, method, article or device including a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements inherent to such process, method, article or device. In the absence of further restrictions, the elements defined by the sentence "comprise a ..." do not exclude the existence of other identical elements in the process, method, article or device including the elements.
[0210] The above description is only a specific embodiment of the present invention, so that those skilled in the art can understand or implement the present invention. Various modifications to these embodiments will be apparent to those skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the present invention. Therefore, the present invention will not be limited to the embodiments described herein, but should conform to the widest scope consistent with the principles and novel features disclosed herein.
Claims
1. A jangliflozin metformin tablet, characterized in that: The janagliflozin metformin tablets include a metformin hydrochloride sustained-release layer, a janagliflozin immediate-release layer and a coating layer; The metformin hydrochloride sustained-release layer comprises: Metformin hydrochloride→1000 parts by weight; Sodium carboxymethyl cellulose → 50.01 parts by weight; Magnesium stearate → 7 parts by weight; Hydroxypropyl methylcellulose → 235 parts by weight; Silicon dioxide → 13 parts by weight; The janagliflozin immediate-release layer comprises: Janagliflozin → 37.488 parts by weight; Lactose → 126 parts by weight; Microcrystalline cellulose → 125.7 parts by weight; Cross-linked sodium carboxymethyl cellulose → 6 parts by weight; Povidone → 2.4 parts by weight; Silicon dioxide → 1.2 parts by weight; Magnesium stearate→1.2 parts by weight; The preparation method of the janagliflozin metformin tablets comprises: (1) Putting the formulated amount of metformin hydrochloride, sodium carboxymethyl cellulose and internal magnesium stearate into a wet granulator, premixing under stirring and shearing, adding purified water, wet granulating, wet granulating, drying, dry granulating to obtain dry granules, mixing the dry granules with the formulated amount of hypromellose and silicon dioxide, and continuing to add external magnesium stearate to mix, to obtain a metformin hydrochloride sustained-release layer mixture; (2) placing the formulated amount of janagliflozin, lactose, microcrystalline cellulose, and internally added croscarmellose sodium into a wet granulator, premixing under stirring and shearing, adding a povidone solution, wet granulating, wet granulating, drying, and dry granulating to obtain dry granules, mixing the dry granules with the formulated amount of externally added croscarmellose sodium and silicon dioxide, and continuing to add magnesium stearate to mix, to obtain a janagliflozin immediate-release layer mixture; (3) The metformin hydrochloride sustained-release layer mixture and the janagliflozin immediate-release layer mixture are compressed into double-layer tablets and coated to obtain the janagliflozin metformin tablets.
2. The janagliflozin metformin tablets according to claim 1, characterized in that The particle size D90 of the metformin hydrochloride is ≤200 μm.
3. The janagliflozin metformin tablets according to claim 1, characterized in that: The step (1) comprises: placing the formulated amount of metformin hydrochloride, sodium carboxymethyl cellulose and internal magnesium stearate into a wet granulator, premixing for 5 min at a stirring rate of 15 Hz and a shear rate of 1500 rmp, adding purified water for a control time of ≤5 min, wet granulating for 2-5 min at a stirring rate of 10-25 Hz and a shear rate of 1500 rmp, wet granulating with an 8-mesh screen, controlling the inlet air temperature to 50-60° C. and the fan frequency to 15-25 Hz to dry the material until the moisture content is ≤1.5% at 40-45° C., drying is completed, performing dry granulation with a 0.8 mm / 1.0 mm screen, and adjusting the finishing speed to 500-1000 rpm to obtain dry granules, mixing the dry granules with the formulated amount of hydroxypropyl methylcellulose and silicon dioxide for 10 min, and continuously adding external magnesium stearate and mixing for 5 min to obtain a metformin hydrochloride sustained-release layer mixture.
4. The janagliflozin metformin tablets according to claim 1, characterized in that: The step (2) comprises: placing the formulated amount of jangliflozin, lactose, microcrystalline cellulose and internally added cross-linked sodium carboxymethyl cellulose into a wet granulator, premixing for 5 min at a stirring rate of 15 Hz and a shear rate of 1500 rmp, adding a povidone solution at a stirring rate of 20-35 Hz and a shear rate of 1500 rmp for a control time of ≤4 min, wet granulating for 2-4 min at a stirring rate of 20-35 Hz and a shear rate of 1500 rmp, using an 8-mesh sieve for wet granulation, controlling the inlet air temperature to 50-60°C for drying until the moisture content of the material is ≤2.8% at 40-45°C, and drying is completed, performing dry granulation with a 0.8mm / 1.0mm sieve, and the finishing speed is 500-1000 rpm to obtain dry granules, mixing the dry granules with the formulated amount of externally added cross-linked sodium carboxymethyl cellulose and silicon dioxide for 10 min, and continuing to add magnesium stearate and mix for 5 min to obtain a jangliflozin immediate-release layer mixture.
5. The janagliflozin metformin tablets according to claim 1, characterized in that: During tableting in step (3), the hardness of the tablet is controlled to be 260-350 N; And / or, in step (3), the coating weight gain is controlled to be 4-5%.
